Biocryst Pharmaceuticals (BCRX) EBT Margin (2010 - 2026)
Biocryst Pharmaceuticals (BCRX) reported EBT Margin of 460.84% for Q1 2026, down 46136.0% on a YoY basis from N/an in Q1 2025, and down 101.32% quarter-over-quarter from 35030.65% in Q4 2025.
Biocryst Pharmaceuticals (BCRX) EBT Margin (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals has reported EBT Margin for 17 years, with the latest figure at 460.84% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin fell 46136.0% year-over-year to 460.84%; the trailing twelve-month figure through Mar 2026 stood at 94.65% (down 8448.0% YoY), and the FY2025 full-year result was 30.56%, up 4986.0% from the prior year.
- EBT Margin for Q1 2026 stood at 460.84%, down from 35030.65% in the prior quarter.
- The five-year high for EBT Margin was 35030.65% in Q4 2025, with the low at 460.84% in Q1 2026.
- Historically, EBT Margin has averaged 1990.89% across 5 years, with a median of 41.29% in 2023.
- Annual changes were most pronounced in 2025 — EBT Margin soared 3505041 bps — and 2026, when it plunged 46136 bps.
- Biocryst Pharmaceuticals' EBT Margin stood at 89.84% in 2022, then climbed by 25 bps to 67.62% in 2023, then soared by 71 bps to 19.76% in 2024, then jumped by 177381 bps to 35030.65% in 2025, then plunged by 101 bps to 460.84% in 2026.
- The last three EBT Margin figures came in at 460.84% (Q1 2026), 35030.65% (Q4 2025), and 7.61% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 10.97% |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 33.51% |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 40.73% |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 25.87% |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 30.30% |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 6.35% |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -156.77% |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 41.45% |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -16.70% |
| 10 | Biocryst Pharmaceuticals | 2.04 Bn | 1.81 Bn | 151.04 Mn | -460.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -460.84% |
| Dec 31, 2025 | 35,030.65% |
| Sep 30, 2025 | 7.61% |
| Jun 30, 2025 | 3.97% |
| Mar 31, 2025 | 0.52% |
| Dec 31, 2024 | -19.76% |
| Sep 30, 2024 | -11.48% |
| Jun 30, 2024 | -11.43% |
| Mar 31, 2024 | -37.75% |
| Dec 31, 2023 | -67.62% |
| Sep 30, 2023 | -41.29% |
| Jun 30, 2023 | -90.42% |
| Mar 31, 2023 | -76.57% |
| Dec 31, 2022 | -89.84% |
| Sep 30, 2022 | -54.07% |
| Jun 30, 2022 | -88.51% |
| Mar 31, 2022 | -148.06% |
| Dec 31, 2021 | -32.92% |
| Sep 30, 2021 | -143.44% |
| Jun 30, 2021 | -86.47% |